Physician profile
Mark Deleon
NPI 1174557649
$9,386.30
in general payments reported to CMS, 2019-2025
65 companies · $2,299 in 2025
The $2,299 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,008 · 2020: $115 · 2021: $640 · 2022: $921 · 2023: $1,837 · 2024: $2,566 · 2025: $2,299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,656 · Education: $45.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,656.27 |
| Education | $45.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $565.33 | 2019-2025 | |
| Astellas Pharma US INC | $530.04 | 2020-2025 | Padcev, Xtandi, Xospata |
| E.R. Squibb & Sons, L.L.C. | $468.17 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Celgene Corporation | $441.58 | 2019-2025 | Reblozyl, Pomalyst |
| Merck Sharp & Dohme LLC | $440.10 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals Lp | $424.73 | 2019-2025 | Calquence, Imfinzi, Enhertu |
| Alexion Pharmaceuticals, INC. | $399.33 | 2019 | |
| Genentech USA, INC. | $391.54 | 2019-2025 | Polivy, Lunsumio, Columvi |
| Janssen Biotech, INC. | $389.78 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Amgen INC. | $385.53 | 2019-2023 | Kyprolis, Lumakras, Evenity |
| Pfizer INC. | $341.80 | 2019-2025 | |
| Glaxosmithkline, LLC. | $321.94 | 2021-2025 | Ojjaara, Blenrep, Jemperli |
| Exelixis INC. | $317.84 | 2023-2025 | Cabometyx |
| Genzyme Corporation | $315.42 | 2019-2024 | |
| Abbvie INC. | $277.83 | 2023-2025 | Venclexta |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $238.69 | 2023-2025 | Libtayo |
| Blueprint Medicines Corporation | $198.02 | 2022-2025 | Ayvakit |
| Eisai INC. | $190.46 | 2019-2025 | |
| Beigene USA, INC. | $159.97 | 2022-2025 | Brukinsa |
| Myriad Genetic Laboratories, INC. | $154.99 | 2021-2022 | |
| Incyte Corporation | $154.39 | 2023-2025 | Monjuvi, Zynyz, Pemazyre |
| Array Biopharma INC | $119.44 | 2019-2025 | Braftovi, Mektovi, Tukysa |
| Daiichi Sankyo INC. | $112.97 | 2022-2025 | Datroway, Enhertu |
| Seagen INC. | $109.23 | 2019-2023 | Padcev, Adcetris, Tukysa |
| Jazz Pharmaceuticals INC. | $105.34 | 2023-2024 | |
| Servier Pharmaceuticals LLC | $85.68 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $85.11 | 2023-2025 | Fruzaqla, Vpriv |
| Gilead Sciences, INC. | $84.11 | 2019-2025 | Trodelvy |
| Beone Medicines USA, INC. | $78.54 | 2025 | Tevimbra, Brukinsa |
| Emd Serono, INC. | $77.99 | 2024-2025 | |
| Adc Therapeutics America, INC. | $76.10 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $74.86 | 2019-2025 | |
| Stemline Therapeutics INC. | $73.37 | 2023-2025 | Orserdu |
| Springworks Therapeutics, INC. | $68.58 | 2024-2025 | Ogsiveo |
| Taiho Oncology, INC. | $66.52 | 2023-2025 | |
| Novocure INC. | $65.12 | 2023-2025 | Optune, Optune Gio |
| Sumitomo Pharma America, INC. | $65.12 | 2023-2024 | Orgovyx |
| Apellis Pharmaceuticals, INC. | $60.66 | 2023-2024 | Empaveli |
| Aveo Pharmaceuticals, INC. | $56.08 | 2023-2025 | Fotivda |
| Kyowa Kirin, INC. | $55.96 | 2023-2025 | Poteligeo |
| Genentech, INC. | $55.64 | 2024 | Columvi, Lunsumio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.10 | 2025 | |
| Karyopharm Therapeutics INC. | $52.77 | 2022-2024 | Xpovio |
| Deciphera Pharmaceuticals INC. | $50.07 | 2023-2024 | Qinlock |
| Ipsen Biopharmaceuticals, INC | $43.61 | 2020-2025 | Onivyde |
| Pharmacosmos Therapeutics INC. | $41.36 | 2024 | Monoferric |
| Progenics Pharmaceuticals, INC. | $41.03 | 2022-2023 | Pylarify |
| Puma Biotechnology, INC. | $37.79 | 2024-2025 | |
| Morphosys, US INC. | $37.09 | 2023-2024 | Monjuvi |
| Foundation Medicine, INC. | $35.14 | 2023 | Foundationone Liquid Cdx |
| Lilly USA, LLC | $33.51 | 2019 | |
| Rigel Pharmaceuticals, INC. | $31.78 | 2022-2025 | Gavreto, Tavalisse, Rezlidhia |
| Octapharma USA, INC. | $22.84 | 2023 | Octagam Immune Globulin (Human) |
| Immunogen, INC. | $22.28 | 2023 | Elahere |
| Recordati_rare_diseases_inc. | $21.54 | 2025 | Enjaymo |
| Sobi, INC | $20.18 | 2025 | |
| Clovis Oncology, INC. | $19.54 | 2021 | |
| Cycle Pharmaceuticals INC | $19.36 | 2025 | Phyrago |
| Kite Pharma, INC. | $19.35 | 2020 | |
| Caris Mpi, INC. | $17.75 | 2025 | Mi Cancer Seek |
| Tersera Therapeutics LLC | $16.97 | 2022 | |
| Tempus Ai, INC | $16.69 | 2024 | Xt Cdx |
| Partner Therapeutics, INC. | $16.04 | 2019 | |
| Myovant Sciences INC. | $16.01 | 2021 | |
| Mirati Therapeutics, INC. | $14.60 | 2023 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Deleon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.